Antivirals and the potential benefits of orally Inhaled Drug Administration in COVID-19 Treatment

Basit Öğe Kaydı
dc.authoridAybige Ertürk / 0000-0002-5179-5865en_US
dc.authorscopusidAybige Ertürk / 57312790100
dc.authorwosidAybige Ertürk / GAQ-1057-2022
dc.contributor.authorŞahin, Gökben
dc.contributor.authorAkbal-Dağıstan, Özlem
dc.contributor.authorÇulha, Meltem
dc.contributor.authorErtürk, Aybige
dc.contributor.authorBaşarır, Nur Sena
dc.contributor.authorYıldız-Peköz, Ayça
dc.date.accessioned2022-06-16T12:04:55Z
dc.date.available2022-06-16T12:04:55Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Temel Bilimleri Bölümüen_US
dc.description.abstractCoronavirus Disease 2019 (COVID-19) pandemic has been on the agenda of humanity for more than 2 years. In the meantime, the pandemic has caused economic shutdowns, halt of daily lives and global mobility, overcrowding of the healthcare systems, panic, and worse, more than 6 million deaths. Today, there is still no specific therapy for COVID-19. Research focuses on repurposing of antiviral drugs that are licensed or currently in the research phase, with a known systemic safety profile. However, local safety profile should also be evaluated depending on the new indication, administration route and dosage form. Additionally, various vaccines have been developed. But the causative virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has undergone multiple variations, too. The premise that vaccines may suffice to eradicate new and all variants is unreliable, as they are based on earlier versions of the virus. Therefore, a specific medication therapy for COVID-19 is crucial and needed in order to prevent severe complications of the disease. Even though there is no specific drug that inhibits the replication of the disease-causing virus, among the current treatment options, systemic antivirals are the most medically appropriate. As SARS-CoV-2 directly targets the lungs and initiates lung damage, treating COVID-19 with inhalants can offer many advantages over the enteral/parenteral administration. Inhaled drug delivery provides higher drug concentration, specifically in the pulmonary system. This enables the reduction of systemic side effects and produces a rapid clinical response. In this article, the most frequently (systemically) used antiviral compounds are reviewed including Remdesivir, Favipiravir, Molnupiravir, Lopinavir- Ritonavir, Umifenovir, Chloroquine, Hydroxychloroquine and Heparin. A comprehensive literature search was conducted to provide insight into the potential inhaled use of these antiviral drugs and the current studies on inhalation therapy for COVID-19 was presented. A brief evaluation was also made on the use of inhaler devices in the treatment of COVID-19. Inhaled antivirals paired with suitable inhaler devices should be considered for COVID-19 treatment optionsen_US
dc.identifier.citationSahin G, Akbal-Dagistan O, Culha M, Erturk A, Basarir NS, Sancar S, Yildiz-Pekoz A. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. J Pharm Sci. 2022 Jun 9:S0022-3549(22)00248-9. doi: 10.1016/j.xphs.2022.06.004. Epub ahead of print. PMID: 35691607; PMCID: PMC9181835.en_US
dc.identifier.doi10.1016/j.xphs.2022.06.004en_US
dc.identifier.issn0022-3549en_US
dc.identifier.pmid35691607en_US
dc.identifier.scopus2-s2.0-85133340283en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttp://doi.org/10.1016/j.xphs.2022.06.004
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2912
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorErtürk, Aybige
dc.language.isoenen_US
dc.publisherElsevier Scienceen_US
dc.relation.ispartofJournal of Pharmaceutical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInhalationen_US
dc.subjectLung Drug Deliveryen_US
dc.subjectPulmonary Drug Deliveryen_US
dc.subjectAerosolen_US
dc.subjectAntiinfectiveen_US
dc.titleAntivirals and the potential benefits of orally Inhaled Drug Administration in COVID-19 Treatmenten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1-s2.0-S0022354922002489-main.pdf
Boyut:
993.16 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Eczacılık Temel Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu